SVB Securities analyst Marc Goodman upgraded Neurocrine to Outperform from Market Perform with a price target of $125, up from $115. The firm thinks that the risk/reward at current levels is very attractive. SVB is also raising its Ingrezza sales estimates once again based on the strong Rx trends. Based on its analysis, the pipeline gets minimal value in the stock, and yet in the second half of 2023 there are a few pipeline catalysts that the firm believes have a good chance of being successful and moving the stock higher.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NBIX: